$BLTE insider trading
Over the last 12 months, Belite Bio insiders reported no purchases and 26 sales totaling $40.5M across SEC Form 4 filings. 92% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $40.5M 26 events
- Events · 12m
- 26 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 92% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Lin Yu-HsinChief Executive Officer · O·D | ▼ Sale | 100,435 | $190 | $19.1M | -58.9% | plan · 19 tranches |
| Sep 8, 2026 | Chuang Hao-YuanChief Financial Officer · O·D | ▼ Sale | 67,395 | $189.98 | $12.8M | -72.1% | plan · 19 tranches |
| Aug 12, 2026 | Chuang Hao-YuanChief Financial Officer · O·D | ▼ Sale | 367 | $180.35 | $66K | -0.4% | plan · 2 tranches |
| Aug 12, 2026 | Lin Yu-HsinChief Executive Officer · O·D | ▼ Sale | 365 | $180.35 | $66K | -0.2% | plan · 2 tranches |
| Jun 18, 2026 | Scholl Hendrik PeterChief Medical Officer · O | ▼ Sale | 10,000 | $145.24 | $1.5M | -40% | 5 tranches · indirect |
| Jun 16, 2026 | Scholl Hendrik PeterChief Medical Officer · O | ▼ Sale | 10,000 | $140.57 | $1.4M | -28.6% | 8 tranches · indirect |
| May 7, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 666 | $153.21 | $102K | -100% | plan · 4 tranches |
| May 6, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $153.84 | $154K | -60% | plan · 6 tranches |
| May 5, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $155.5 | $156K | -37.5% | plan · 6 tranches |
| May 4, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $155.64 | $156K | -27.3% | plan · 5 tranches |
| May 1, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $155.78 | $156K | -21.4% | plan · 8 tranches |
| Apr 30, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $156.97 | $157K | -17.6% | plan · 4 tranches |
| Apr 29, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $155.82 | $156K | -15% | plan · 5 tranches |
| Apr 28, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $159.16 | $159K | -13% | plan · 9 tranches |
| Apr 27, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $162.64 | $163K | -11.5% | plan · 5 tranches |
| Apr 24, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $159.56 | $160K | -10.3% | plan · 6 tranches |
| Apr 23, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $166.28 | $166K | -9.4% | plan · 6 tranches |
| Apr 22, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $170.38 | $170K | -8.6% | plan · 9 tranches |
| Apr 21, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $166 | $166K | -7.9% | plan · 5 tranches |
| Apr 20, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $163.59 | $164K | -7.3% | plan · 7 tranches |
| Apr 17, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $161.63 | $162K | -6.8% | plan · 6 tranches |
| Apr 16, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $160.38 | $160K | -6.4% | plan · 7 tranches |
| Apr 15, 2026 | MATA NATHAN L.Chief Scientific Officer · O | ▼ Sale | 1,000 | $168.3 | $168K | -6% | plan · 5 tranches |
| Apr 9, 2026 | Lin Yu-HsinChief Executive Officer · O·D | ▼ Sale | 9,200 | $181.45 | $1.7M | -5.1% | plan · 4 tranches |
| Apr 9, 2026 | Chen Wan-ShanD | ▼ Sale | 1,100 | $180.43 | $198K | -10.8% | plan |
| Apr 9, 2026 | Chuang Hao-YuanChief Financial Officer · O·D | ▼ Sale | 6,200 | $181.5 | $1.1M | -6.2% | plan · 4 tranches |
Every $BLTE filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Belite Bio filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $BLTE feed.